Visiongain has published a new report entitled Next Generation Sequencing Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): Forecasts by Type (Consumables, Bioinformatics, Sequencing Services, Pre-sequencing Services, Instruments), by Workflow (Library Preparation, Sequencing, Data Analysis), by Application (Oncology, Reproductive Health, Genetic and Rare Diseases, Consumer Genomics, Agrigenomics & Forensics, Others), by End-users (Hospitals and Clinics, Academic and Research Institutes, Pharmaceutical and Biotech Companies, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

The global Next Generation Sequencing market is estimated at US$11,533.5 million in 2025 and is projected to grow at a CAGR of 20.7% during the forecast period 2025-2035.

Impact of US Trade Tariffs on the Global Next Generation Sequencing Market  

The imposition of US trade tariffs is adding a new layer of uncertainty to the next generation sequencing (NGS) sector. With a large share of sequencing instruments and consumables relying on imports of precision components, tariffs threaten to inflate costs across the supply chain. Research organisations and healthcare providers, already working within constrained budgets, may see projects delayed or scaled back as procurement costs rise. This risks slowing down the broader adoption of sequencing in clinical diagnostics, drug development, and population genomics, precisely at a time when governments and institutions are looking to expand access.

For the industry as a whole, tariffs may encourage supply chain reorganisation but at the expense of efficiency. Larger players may offset risks by building local capacity or negotiating long-term agreements, while smaller firms and sequencing service providers face tighter margins and greater exposure. Globally, the move could trigger a push for regional self-sufficiency, with Asia and Europe accelerating efforts to reduce dependency on US suppliers. Such fragmentation may weaken the collaborative spirit that has driven innovation in genomics, potentially delaying the next wave of breakthroughs in precision medicine.

Expanding Role of NGS in Biomarker Discovery and Drug Development

The growing adoption of NGS in biomarker discovery and drug development presents a significant opportunity for market expansion. NGS enables the identification of genetic markers linked to disease progression, treatment response, and adverse drug reactions. By providing a detailed understanding of genomic variations, it has become indispensable for the development of targeted therapies and companion diagnostics. These capabilities not only improve patient outcomes but also enhance the efficiency of clinical decision-making.

NGS data is increasingly being integrated into drug discovery pipelines, where it provides insight into disease mechanisms, identifies new therapeutic targets, and supports both preclinical and clinical trial design. Pharmaceutical companies are using NGS-driven biomarker strategies to stratify patient populations, reduce trial failure rates, and shorten development timelines. For example, in oncology, companion diagnostics based on sequencing technologies are now routinely paired with immunotherapies and targeted treatments to ensure patients most likely to respond are selected.

The use of NGS in biomarker discovery and drug development is expected to grow further as precision medicine becomes embedded in healthcare systems worldwide. With the increasing complexity of disease biology and the rising demand for personalised therapies, sequencing-based approaches will remain critical to advancing next-generation drugs. This creates long-term opportunities for technology providers, service companies, and pharmaceutical firms seeking to integrate genomic data into the full lifecycle of therapeutic innovation.

How will this Report Benefit you?

Visiongain’s 336-page report provides 126 tables and 219 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the Next Generation Sequencing market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Next Generation Sequencing. Get financial analysis of the overall market and different segments including type, process, upstream, downstream, and company size and capture higher market share. We believe that there are strong opportunities in this fast-growing Next Generation Sequencing market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Declining Costs of Sequencing as a Key Driver of Adoption

The cost of whole-genome sequencing (WGS) has fallen at an extraordinary pace over the past two decades, from nearly US$100 million per genome in 2001 to under US$1,000 today. This rapid decline has made next-generation sequencing (NGS) increasingly accessible for research institutions, hospitals, and pharmaceutical companies. Factors such as automation, platform miniaturisation, and increased competition between suppliers have been central to this cost reduction, while economies of scale have further accelerated affordability.

As sequencing becomes more affordable, clinical acceptance is rising in oncology, rare disease diagnostics, and infectious disease management. Lower costs have also encouraged its use in non-traditional areas, such as agriculture, where sequencing crop genomes that once cost tens of thousands of dollars can now be done at a fraction of the price. Similarly, microbiology laboratories can integrate sequencing into pathogen tracking at much lower budgets, making advanced genomics tools available to a far wider range of users.

The falling cost curve is expected to continue reshaping the market by enabling broader global participation, particularly in emerging economies where budget limitations have historically hindered access. This democratisation of sequencing is one of the strongest drivers of NGS growth and is likely to remain so throughout the forecast period.

Research and Clinical Collaborations Accelerating Uptake

Partnerships between research institutions, healthcare providers, and technology developers are playing a pivotal role in expanding the use of NGS. These collaborations bring together complementary expertise, helping to translate genetic discoveries into tangible clinical applications. By aligning academic innovation with clinical need and industrial resources, such partnerships accelerate the development of evidence-based genomic medicine.

A notable example came in November 2024, when Oxford Nanopore Technologies partnered with the UK’s National Health Service (NHS) to deploy its long-read sequencing technology across up to 30 NHS sites. The initiative is designed to establish an early-warning system for infectious diseases, enabling pathogen detection and treatment recommendations within six hours of sample collection. This not only strengthens the UK’s preparedness for future pandemics but also demonstrates how collaborative models can integrate advanced sequencing into routine healthcare.

Similar collaborations are also evident globally. In the United States, alliances between academic centres and biopharmaceutical companies have helped embed sequencing into drug discovery pipelines, while in Asia, partnerships between government-funded institutes and private players are expanding the use of NGS in population-wide genomics initiatives. Such collaborations are essential to market growth as they both validate the technology’s utility and reduce barriers to adoption.

Where are the Market Opportunities?

Expanding Potential Through Technological Advancements

Ongoing technological innovation remains one of the strongest opportunities in the NGS market. Advances in sequencing chemistry, instrument engineering, automation, and bioinformatics have significantly improved accuracy, speed, and scalability, making NGS increasingly attractive for both research and clinical settings. Each new generation of platforms reduces turnaround times while lowering costs, broadening access to genomics globally.

In August 2024, Illumina expanded the cancer testing menu for its NovaSeq X Series, enabling larger-scale genetic profiling at reduced costs. This development not only supports cancer research but also demonstrates how incremental innovation can create major opportunities for clinical adoption. As workflows become more efficient, sequencing is moving from being a specialised tool to a routine component of diagnostics and population-scale genomics initiatives.

The rapid pace of innovation ensures that NGS will continue to penetrate new fields such as infectious disease surveillance, agriculture, and environmental monitoring, while deepening its role in oncology and genetic research. For investors and technology providers, these advancements present strong growth prospects by continually opening new avenues of application.

Growth Prospects in Personalised Medicine and Precision Oncology  

Personalised medicine is one of the most powerful growth frontiers for NGS, particularly in oncology. By sequencing entire genomes or targeted panels, NGS provides clinicians with insights into genetic variations that influence disease risk, treatment response, and drug metabolism. This enables more accurate patient stratification and treatment selection, ensuring therapies are better tailored to the individual.

The opportunity is being reinforced by the global rise in cancer incidence. According to the International Agency for Research on Cancer (IARC), ageing populations and demographic growth are projected to result in 27.5 million new cancer cases and 16.3 million deaths annually by 2040. This rising burden underscores the urgency of precision oncology solutions, where NGS is already proving indispensable.

Beyond oncology, personalised medicine is extending into cardiology, neurology, and rare disease treatment. Biopharmaceutical companies are increasingly using NGS to support drug development pipelines, biomarker discovery, and companion diagnostic design. The growing integration of genomics into healthcare systems worldwide signals a long-term structural opportunity for the NGS market.

Competitive Landscape

The major players operating in the Next Generation Sequencing market are 10X Genomics, Agilent Technologies, Inc., BGI Group, Bio-Rad Laboratories, Inc., Eurofins Scientific, F. Hoffman-La Roche Ltd, Illumina, Inc., Oxford Nanopore Technologies plc, PacBio, PerkinElmer, QIAGEN, Takara Bio Inc., and Thermo Fisher Scientific Inc. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.

Recent Developments

• On 11^th August 2025, Eurofins Genomics Europe announced the strategic relocation of its Next Generation Sequencing (NGS) operations from Constance to Ebersberg, Germany. This move is part of the company’s broader initiative to enhance operational efficiency, expand service capacity, and strengthen its presence across Europe.
• On 5^th May 2025, PacBio and Chulalongkorn University announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as part of a newborn screening research program. This marks the first initiative in Asia Pacific to explore the use of PacBio’s HiFi sequencing technology at population scale – an effort designed to evaluate how comprehensive genomic data can support earlier, more accurate identification of rare and treatable conditions in newborns. The collaboration highlights Thailand’s growing leadership in precision medicine and offers a potential model for countries seeking to modernize newborn screening with genome-wide approaches.
• On 2^nd May 2024, QIAGEN launched QCI Secondary Analysis, a new cloud-based secondary analysis solution for oncology and inherited disease applications that enables high-throughput data analysis with limited resource and infrastructure investment.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.